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Chia-Hui Chen1 and Shih-Ku Lin2,3*Abstract
Background: Carbamazepine (CBZ) has been used in the treatment of bipolar disorder, both in acute mania and
maintenance therapy, since the early 1970s. Here, we report a follow-up study of CBZ-treated bipolar patients in the
Taipei City Psychiatric Centre.
Methods: Bipolar patients diagnosed according to the DSM-IV system and treated with CBZ at the Taipei City
Psychiatric Centre had their charts reviewed to evaluate the efficacy and side effects of this medication during an
average follow-up period of 10 years.
Results: A total of 129 bipolar patients (45 males, mean age: 45.7 ± 10.9 year) were included in the analysis of CBZ
efficacy used alone (n = 63) or as an add-on after lithium (n = 50) or valproic acid (n = 11), or the both of them
(n = 5). The mean age of disease onset was 24.6 ± 9.5 years. The mean duration of CBZ use was 10.4 ± 5.2 year. The
mean dose used was 571.3 ± 212.6 mg/day with a mean plasma level of 7.8 ± 5.9 μg/mL. Mean body weight
increased from 62.0 ± 13.4 kg to 66.7 ± 13.1 kg during treatment. The frequencies of admission per year before and
after CBZ treatment were 0.33 ± 0.46 and 0.14 ± 0.30, respectively. The most common side effects targeted the
central nervous system (24%), including dizziness, ataxia and cognitive impairment. Other common side effects
were gastrointestinal disturbances (3.6%), tremor (3.6%), skin rash (2.9%), and blurred vision (2.9%). Eighty-eight
patients (68.2%) were taking antipsychotics concomitantly. Ninety-six patients (74.4%) needed to use
benzodiazepines concomitantly. Sixty-three (48.8%) patients had zero episodes in a 10-year follow-up period,
compared to all patients having episodes prior to treatment. Using variable analysis, we found better response to
CBZ in males than in females.
Conclusions: CBZ is efficacious in the maintenance treatment of bipolar disorder in naturalistic clinical practice,
either as monotherapy or in combination with other medications. CBZ is well tolerated by most patients in this
patient group.
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Relapse in patients with bipolar disorder is a common
problem. More than 90% of patients will have a recur-
rent episode, and it is also the cause of long-term mor-
bidity and mortality [1,2]. Due to the chronic nature of
this illness, there is a need for long-term maintenance
treatment to prevent or attenuate the risk of relapse [3].* Correspondence: sklin@tpech.gov.tw
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reproduction in any medium, provided the orLithium is the classic mood stabilizer used in treating
acute and chronic bipolar disorder. However, studies
have suggested that an estimated 20–40% of patients
may have an inadequate prophylactic response to this
drug [4,5]. Undesirable side effects and a narrow thera-
peutic index also make it less than ideal for many
patients. This has led to efforts to investigate the poten-
tial utility of other mood stabilizers in maintenance
therapy.
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ible with lithium in the treatment of acute mania in
small-scale trials [9,10]. In Taiwan, CBZ has been in-
creasingly used to treat bipolar disorder [11]. Its efficacy
for treating acute mania was recently reconfirmed follow-
ing the completion of large-scale, randomized, placebo-
controlled trials in North America using extended-release
CBZ [12,13].
Despite the widespread clinical use of mood-stabilizer
combinations for the long-term treatment of patients with
bipolar disorder, research on the risks and benefits of this
practice is limited. In recent decades, only a few studies
have focused on the use of CBZ for the maintenance of
bipolar disorder [14-18]. The results of a 2-year follow-up
study showed approximately equal effects when compar-
ing CBZ and lithium in the prevention of mood episodes
[18]. In a small-scale clinical trial comparing CBZ and pla-
cebo [19], the prophylactic effects of CBZ were superior in
bipolar patients. However, several meta-analyses were un-
able to reach a conclusion about the efficacy of CBZ in
prophylaxis [20-22]. In addition, there are a number of
limitations when interpreting previous double-blind, con-
trolled studies [23]. Firstly, most of these studies were
based on a small sample size (up to 60 patients). Second,
follow-up periods were relatively short (up to 2.5 years).
Studies concerned with long-term efficacy tend to be more
rigorous when their follow-up periods are longer. Unfortu-
nately, studies that address the above-mentioned limita-
tions are scarce. Therefore, we aimed to evaluate the
clinical usage and long-term efficacy of CBZ in patients
with bipolar I disorder treated with CBZ over an extended
period. We reviewed the charts of a sample of 129 patients
maintained on long-term CBZ therapy for up to 10 years.
This paper describes the demographics, clinical character-
istics and outcome data, and analyses the correlates of the
outcome.Methods
Setting and subjects
This was a retrospective chart-review study. Subjects
comprised of patients attending the outpatient clinic
of the Taipei City Psychiatric Center (TCPC) in Taipei,
Taiwan. TCPC is a psychiatric hospital of 600 beds, and is
one of the oldest and largest psychiatric hospitals in the Tai-
pei metropolitan area. Most patients attending this hospital
were referred from other general hospitals or clinics, and
had been regularly followed up on. We included patients
with a DSM-IV diagnosis of bipolar I disorder who
had been treated at this hospital for at least 1 year
with prophylactic CBZ (TegretalW) either as mono-
therapy or combined with other mood stabilizers or
antipsychotics. Diagnoses were made according to the
medical records of the patient, and were usually madeby at least two well-trained psychiatrists based on clin-
ical evaluation and observation.
Assessment
The study was based on a mirror-image study design, in
which the clinical course under CBZ treatment was
compared with data prior to CBZ treatment. The fre-
quency of manic or depressive episodes and the fre-
quency of hospitalization were recorded and analyzed as
the main outcomes. We also collected clinically relevant
data from the medical records and phone interviews, in-
cluding demographic data, duration of illness and CBZ
use, dosage and plasma concentration, concomitant
medications, and reported side effects. The data were
obtained by experienced research assistants, and the ac-
curacy of recording was verified by two senior psychia-
trists. Patients usually visited the clinic once a month
but the frequency was dependent upon their clinical
condition. An episode was defined as the recurrence of a
full-blown manic or depressive mood event recorded in
the chart. Patients who were prescribed with CBZ after
their first episode were coded as ‘one episode prior to
CBZ treatment’. The serum level of CBZ and other para-
meters were regularly monitored about twice a year, ap-
proximately 12 hours after the last dose of CBZ.
Concomitant usage of medications other than CBZ was
determined by clinical condition of the patient and was
not limited due to the naturalistic nature of this study.
We recorded the medications used at the last visit. We
divided the patients into those with complete remission
(CR) and those with non-CR, in which they had relapsed
episode after CBZ treatment. This study was approved
by the institutional review board of the hospital.
Data analysis
The clinical variables were analyzed as mean ± SD.
Paired t-test was utilized to analyze the changes in
affective episodes before and after CBZ use. Independent
t-test and Chi-square test were used to clarify correla-
tions between variables and the treatment response.
Results
Characteristics of patients
A total of 129 (45 males) patients were recruited in this
study. Table 1 shows the basic demographic and clinical
characteristics of these patients. Their ages ranged from
22 to 80 years, but most (84.5%) were between 30 to
60 years old. Forty-four percent were married. Forty-one
percent of the patients were in full-time or part-time
employment, 23% were housewives, and 26% were un-
employed. Most patients were judged to be regular
attendees at follow-up and showed good drug compli-
ance. The mean duration of disease course before CBZ
treatment was 10.8 ± 7.6 years. Forty-two had started
Table 1 Clinical characteristics of study subjects (n = 129)
Clinical characteristics Mean± SD
Age (years) 45.7 ± 10.9
Age of onset (years) 24.6 ± 9.5
Education (years) 11.8 ± 3.3
Latency to CBZ treatment (Years) 10.8 ± 7.6
Follow-up period after CBZ treatment (Years) 10.4 ± 5.2
Current CBZ dose (mg) 571.3 ± 212.6
Current CBZ plasma level (μg/mL) 7.8 ± 5.9
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switched to CBZ after receiving lithium or valproic acid.
For the remainder, CBZ was used as an add-on to lith-
ium (n = 45), valproic acid (n = 11), or the both of them
(n = 5). Eighty-eight patients (68.2%) were taking low-
dose antipsychotics concomitantly. Ninety-six patients
(74.4%) needed to use benzodiazepines (mostly for the
hypnotic action) concomitantly. CBZ monotherapy
(without other mood stabilizer or antipsychotic) was
used in 20 patients (15.5%). Among them, 12 patients
were in the CR group. The patients’ mean body weight
increased from 61.8 ± 13.2 to 66.6 ± 12.8 kg during treat-
ment. The body weight increment was significantly less
in patients treated with CBZ than those with combin-
ation of lithium, or valproic acid (3.41 ± 8.81 vs.
7.23 ± 10.60 kg, mean difference =−3.83, 95% CI =−7.64
to −0.01, p = 0.050), regardless of any combined use of
antipsychotics. The mean number of admissions before
and after CBZ was 2.26 ± 2.25 and 1.19 ± 1.80, respect-
ively. After CBZ treatment, almost half of the patients
(n = 63, 48.8%) had no further mood episodes during the
follow-up period. Others (n = 66, 51.2%) suffered from
varying frequencies of relapses ranging from 1 to 15
relapses.
Effectiveness of CBZ
Table 2 shows the mean frequency (times per year) of
hospitalization and mood episode pre- and post-CBZtreatment. Compared to the pre-CBZ treatment period,
the post-CBZ period showed significantly fewer hospital
admissions per year (p< 0.001), and fewer mood epi-
sodes per year (p = 0.002).Variables correlated with treatment response
We also delineated the correlates and characteristics of a
good or poor response. Using our definition of CR and
non-CR according to whether they had relapsed after
CBZ treatment, 63 patients were placed in the CR group
and 66 patients in the non-CR group. These two groups
were then compared with respect to demographics and
clinically-related variables. Data on the variables are pre-
sented in Table 3. The CR patients had a shorter follow-
up duration after CBZ treatment (p = 0.046), a trend of
fewer mood episodes before CBZ treatment (p = 0.054),
and a higher likelihood of being male (p = 0.026).
The most common side effects recorded on the chart
were related to the central nervous system (24%), such as
dizziness, ataxia, and cognitive impairment. Other com-
mon side effects were gastrointestinal disturbance (3.6%),
tremor (3.6%), skin rash (2.9%), and blurred vision (2.9%).Discussion
To our knowledge, this is the longest outcome study
that addresses the long-term use of CBZ in bipolar
patients. We collected data from 129 patients exhibiting
good compliance and attendance, which implies a rea-
sonable quality of data. We used chart review to
minimize the effect of recall bias, and all patients were
evaluated by experienced clinicians. It is also worth not-
ing that the long follow-up period (mean duration of
10 years) in this study could provide information that
other studies lack. Mean plasma level of patients was
7.8 ± 5.9 μg/mL, which was within suggested therapeutic
range for maintenance therapy.
We found that the frequency of mood episodes and
hospitalization decreased significantly after CBZ treat-
ment. We were also surprised to find that almost half of
the patients (48.8%) had no more mood episodes after
CBZ treatment, showing the efficacy of CBZ, either as
monotherapy or combined with other mood stabilizers
or antipsychotics, in the prophylactic treatment of bipo-
lar disorder. It is difficult to compare our findings with
other studies since there has been no other 10-year nat-
uralistic follow-up of bipolar disorder patients treated
with CBZ. The response rates for CBZ in previous stud-
ies varied. Kleindienst and Greil [24] found that classical
bipolar patients treated with CBZ had a hospitalization
rate of about 62% versus 26% in those treated with lith-
ium in a randomized clinical trial with an observation
period of 2.5 years. The better remission rate in our
study might be related to the naturalistic design of the
Table 2 Frequency (Mean ± SD times/year) and mean difference of hospitalization and mood episode before and after
carbamazepine (CBZ) treatment
Before CBZ After CBZ Mean difference (95%CI) P value
Hospitalization frequency 0.33 ± 0.46 0.14 ± 0.30 0.18 (0.09, 0.27) <0.001
Episode frequency 0.63 ± 1.70 0.16 ± 0.30 0.47 (0.17, 0.77) 0.002
SD standard deviation, CI confidence interval.
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tions during the study period.
A second aim of our study was to determine the corre-
lates of the CBZ prophylactic response. In previous stud-
ies, CBZ response was related to “non-classical disease”,
and patients with suicidal behavior, lithium-refractory
disease, and mixed episodes. However, in our study, no
specific factors were correlated with the response to
CBZ treatment with the exception that males had a bet-
ter response rate. Since it was impossible to attain some
of the clinical variables in this retrospective review, the
response may be correlated with other factors that were
not considered in this study.
The adverse events reported by the patients were also
reviewed. The most common side effects coded were
dizziness, fatigue and somnolence (24%). Most patients
in our study were able to tolerate the side effects of
long-term use of CBZ. Patients who did not receive con-
comitant lithium or valproic acid had significantly less
body weight increment. This result confirms previousTable 3 Comparison of clinical variables between subjects wi
and relative risk (RR)
Variables CR (n = 63) with
Mean± SD Mea
Latency to CBZ treatment (yrs) 11.86 ± 8.07 9.70
Period after CBZ treatment (yrs) 9.49 ± 5.04 11.3
Episode before treatment 2.57 ± 2.13 3.32
Episode after treatment 0 2.65
Drug dose (mg) 539.68 ± 187.98 601.
Drug level (μg/mL) 7.22 ± 1.94 8.38
Age (yrs) 46.99 ± 11.17 44.5
N (%) N (%
Gender (female) 35 (55.6) 49 (7
Tobacco use 9 (14.5) 15 (2
Alcohol use n 5 (8.1) 5 (7.
Combined use of antipsychotics 36 (57.1) 52 (7
Combined use of BZD n 45 (71.4) 51 (7
Combined use of lithium 24 (38.1) 26 (3
Combined use of valproic acid 10 (15.9) 6 (9.
Combined use of antidepressant 6 (9.5) 8 (12
CBZ carbamazepine, SD standard deviation, CI confidence interval, BZD benzodiazepreports [14,21] suggesting that one benefit of CBZ in-
clude the low propensity toward weight gain and evi-
dence of good tolerability with long-term treatment.
It is worth noting that about 40% of patients were
treated concomitantly with lithium or valproic acid.
Most patients needed benzodiazepines (74.4%) and anti-
psychotics (68.2%) in maintenance therapy. Given the
naturalistic study design, we were unable to control the
adjuvant medication. However, adjuvant medication
usage did not differ between our CR and non-CR
groups. In a review article by Keck and McElroy [25],
the authors suggested that combination therapy may
provide better long-term prevention of illness relapse
and recurrence in many patients with bipolar disorder.
The main limitation of this study was the potential for
a confounding bias due to its observational design. Since
this study was designed as a retrospective chart review,
it did not include patients who were initially treated with
CBZ but discontinued use later for any reason. It was
difficult to estimate the percentage of patients whoth/without complete remission (CR) by mean difference
out CR (n= 66)
n± SD Mean difference (95% CI) P value
± 6.96 2.16 (−0.47, 4.78) 0.106
1± 5.23 −1.82 (−3.61, −0.03) 0.046
± 2.23 −0.75 (−1.51, 0.01) 0.054
± 1.86 −2.65 (−3.11, −2.19) <0.001
52 ± 231.05 −61.83 (−135.42, 11.75) 0.099
± 8.03 −1.15 (−3.26, 0.95) 0.280
5± 10.58 2.44 (−1.35, 6.23) 0.205
) RR (95% CI) P value
4.2) 0.75 (0.58, 0.97) 0.026
2.7) 1.11 (0.94, 1.31) 0.234
6) 1.00 (0.90, 1.10) 0918
8.8) 2.02 (1.17, 3.49) 0.008
7.3) 1.26 (0.70, 2.27) 0.447
9.4) 1.02 (0.78, 1.34) 0.880
1) 0.93 (0.81, 1.06) 0.243
.1) 1.03 (0.91, 1.16) 0.635
ine.
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should be interpreted with caution, and may only reflect
the prophylactic effect in those who initially responded
to acute treatment with CBZ. It is likely that patients
who did not respond well to CBZ or who did not toler-
ate CBZ were more likely to drop out. In a 6-month,
multicenter, open-label evaluation of beaded, extended-
release CBZ capsule monotherapy in bipolar disorder
patients with manic or mixed episodes [26], 68.8% of
patients discontinued treatment early due to the lack of
efficacy or side effects. This result reflects the fact that
only a portion of patients adhere to CBZ according to
perceived efficacy or tolerability of side effects. Our
study merely showed that if a patient had a fair response
to CBZ, they were likely to respond well in the continu-
ing follow-up period. As mentioned earlier, due to the
naturalistic setting, medications were not controlled dur-
ing relapse. In addition, some variables were not
reviewed (e.g., rapid cycling, or type of mood episode),
which limited further analysis of clinical outcomes.
Patients who were prescribed with CBZ during their first
episode were coded as ‘zero episode prior to CBZ treat-
ment’, which included 42 of the subjects. It is possible
that patients with bipolar disorder who had just one epi-
sode over a long period of time may have a milder bipo-
lar illness. However, after excluding these 42 subjects
from analysis, the results remained the same (data not
shown).Conclusions
As demonstrated, our longitudinal study proved that
CBZ is efficacious and tolerable in the maintenance ther-
apy of bipolar disorder in naturalistic clinical practice,
either as monotherapy or in combination with other
medications. Patients who have a good response to CBZ
tend to continue to do well over the long term and their
subsequent course of illness appears to be improved
compared to their course of illness prior to CBZ treat-
ment. This should be validated by more controlled long-
term follow-up studies.Competing interests
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